Article Information
History
- February 7, 2018.
Article Versions
- Version 1 (December 4, 2017 - 19:43).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Ana Crespillo-Casado1,*,
- Zander Claes2,
- Meng S. Choy3,
- Wolfgang Peti3,
- Mathieu Bollen2 and
- David Ron1,*
- 1Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, United Kingdom;
- 2Department of Cellular and Molecular Medicine, KU Leuven, BE-3000 Leuven, Belgium;
- 3Department of Chemistry and Biochemistry, University of Arizona, Tucson, Arizona 85721-0041, United States
- ↵*To whom correspondence should be addressed: Ana Crespillo-Casado & David Ron: Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Wellcome Trust/MRC Building, Hills Road, Cambridge CB2 0XY, United Kingdom; ac880{at}cam.ac.uk & dr360{at}medschl.cam.ac.uk; Phone 01223 768 940
Posted February 07, 2018.
Choice of PP1 catalytic subunit affects neither requirement for G-actin nor insensitivity to Sephin1 of PPP1R15A-regulated eIF2αP dephosphorylation
